AstraZeneca has revealed it has expanded membership of its Senior Executive Team, which comes into effect immediately. The new changes include increased representation of the company’s ...

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

AstraZeneca and Pfizer have announced a new approach to drug development, through a public-private partnership with the Quebec government. The three partners aim to bridge the gap between early ...

Covid vaccine compensation could be given to thousands left 'disabled' by the AstraZeneca jab, it has emerged. Health Secretary Wes Streeting is understood to be considering plans to set up a ...

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

AstraZeneca will pay CSPC $100 million upfront, with potential for up to $1.92 billion in milestone payments. Airsupra Phase 3b trial shows significant reduction in severe asthma exacerbations ...

The facility was inaugurated by Dr TRB Rajaa, Tamil Nadu's Minister of Industries, alongside British Deputy High Commissioner Christina Scott CMG and AstraZeneca's leadership team. Celebrating its ...

Oct 7 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd (1093.HK), opens new tab in an exclusive licence agreement to ...

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) ...

AstraZeneca said on Monday (Oct 7) it would pay up to US$1.92 billion to CSPC Pharmaceutical Group in an exclusive licence agreement to boost the Anglo-Swedish drugmaker’s cardiovascular pipeline.

Astrazeneca (AZN) has been beaten down lately with too much selling pressure. While the stock has lost 5.3% over the past four weeks, there is light at the end of the tunnel as it is now in ...